St Louis, Missouri – By recruiting the immune system to combat tumor cells, immunotherapy has improved survival rates, offering hope to millions of cancer patients. However, only about one in five people responds favorably to these treatments. With a goal of understanding and addressing immunotherapy’s limitations, researchers at Washington University...
treatment News
Arlington, TX – Lung cancer is not the most common form of cancer, but it is by far the deadliest. Despite treatments such as surgery, radiation therapy and chemotherapy, only about a quarter of all people with the disease will live more than five years after diagnosis, and lung cancer...
Houston, TX – Researchers at The University of Texas MD Anderson Cancer Center showed that altering the sequence of breast cancer treatment to administer radiation before mastectomy allowed for concurrent breast reconstruction surgery, which reduced the number of operations required, minimized treatment delays and improved patient satisfaction. The Phase II...
MENLO PARK, Calif. & GENEVA, Switzerland — AN2 Therapeutics, Inc. (Nasdaq: ANTX) and the non-profit medical research organization Drugs for Neglected Diseases initiative (DNDi) today announced a collaboration to advance clinical development of AN2-502998, AN2’s oral drug candidate in development for the treatment of chronic Chagas disease. Chagas disease is...
MENLO PARK, Calif. — AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating the safety, efficacy, and pharmacokinetics of epetraborole, an orally administered inhibitor of leucyl-tRNA synthetase...
MENLO PARK, Calif. — AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to expand the development of oral epetraborole into a Phase 2 proof-of-concept clinical study in adults with phlebotomy-dependent polycythemia vera (PV). PV...
MENLO PARK, Calif. — AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in November. Stifel 2023 Healthcare Conference Eric Easom, Co-Founder, President...
Anacor Pharmaceuticals, a biopharmaceutical company engaged in the development of small molecule drugs, has entered into a licensing and research agreement with not-for-profit Global Alliance for TB Drug Development or TB Alliance to explore a novel anti-bacterial drug target for use in tuberculosis therapy. Under the agreement, Anacor will provide...
NEW YORK, NY – A Ludwig Cancer Research study has generated a granular portrait of how the cellular and molecular components of the blood vessels that feed brain metastases of melanoma and lung and breast cancers differ from those of healthy brain tissue, illuminating how they help shape the internal...
NEW YORK – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, reported predictive biomarker of response established with SIGMAR1...